Sirio Pharma Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Peiqing Li

Chief Executive Officer (CEO)

CN¥1.8m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	9.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?

Oct 14

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sep 30

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Apr 24

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06

CEO

Peiqing Li (59 yo)

no data

Permanencia

CN¥1,842,800

Compensación

Mr. Peiqing Li has been Chairman of the Board and General Manager at Sirio Pharma Company Limited since April 23, 2015 and serves as its Non-Independent Director.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peiqing Li	GM & Chairman of the Board	no data	CN¥1.84m	9.21% CN¥ 565.0m
Qiong Chen	Deputy GM & Director	9.6yrs	CN¥1.62m	7.48% CN¥ 459.1m
Rui Yang	Director	9.6yrs	CN¥120.00k	3.26% CN¥ 200.0m
Zhuangmin Yao	Director	9.6yrs	CN¥1.77m	2.65% CN¥ 162.8m
Guilong Zhu	Independent Director	3.3yrs	CN¥120.00k	sin datos
Shiming Hu	Independent Director	3.3yrs	CN¥120.00k	sin datos
Jian Gao	Independent Director	3.3yrs	CN¥120.00k	sin datos
Meibin Zhang	Non-Employee Supervisor	3.3yrs	sin datos	sin datos
Shaoqin, Zhu	Supervisor	2.1yrs	sin datos	sin datos

3.3yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 300791 se considera experimentada (3.3 años de antigüedad promedio).

Sirio Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥1.22 (vs CN¥0.36 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sirio Pharma Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 29%

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Price target decreased by 7.2% to CN¥29.75

Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023)

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Now 21% overvalued

Now 21% overvalued

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investor sentiment deteriorates as stock falls 27%

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Price target increased by 7.8% to CN¥41.67

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021)

Now 22% undervalued

Now 23% undervalued

Now 20% undervalued

Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

Now 23% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sirio Pharma Co., Ltd. Approves Final Divided for 2020

Sirio Pharma Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019)

New 90-day low: CN¥83.31

Investor sentiment deteriorated over the past week

New 90-day high: CN¥113

Investor sentiment improved over the past week

New 90-day low: CN¥84.38

New 90-day low: CN¥86.60

Third quarter earnings released

Market bids up stock over the past week

New 90-day high - CN¥116

Earnings released

Sirio Pharma Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥89.00

Sirio Pharma Co., Ltd. announced a financing transaction

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media